Mechanisms of multiple sclerosis

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 4, 2005, Pages 447-452

  Lassmann, Hans ^a  

^a Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; ALEMTUZUMAB; ATORVASTATIN; BETA INTERFERON; CLADRIBINE; CNTO 1275; CORTICOSTEROID; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN; DACLIZUMAB; ESTRIOL; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; IMMUNOGLOBULIN; INTERLEUKIN 12 ANTIBODY; LAMOTRIGINE; LAQUINIMOD; LIGAND; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; PEPTIDE; PLACEBO; RAPAMYCIN; RILUZOLE; RITUXIMAB; SIMVASTATIN; TERIFLUNOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNITY; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; CLINICAL TRIAL; DEMYELINATING DISEASE; DISEASE CLASSIFICATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; PATHOGENESIS; PLASMAPHERESIS; REVIEW;

EID: 33645061258     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.11.007     Document Type: Review

References (58)

1. J.H. Noseworthy et al. Multiple sclerosis N. Engl. J. Med. 343 2000 938-952
2. F.D. Lublin S.C. Reingold Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Neurology 46 1996 907-911
3. R. Hohlfeld H. Wekerle Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines Proc. Natl. Acad. Sci. U S A 101 Suppl. 2 2004 14599-14606
4. H. Wekerle et al. Cellular immune reactivity within the CNS Trends Neurosci. 9 1986 271-277
5. N. Kawakami et al. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis J. Exp. Med. 199 2004 185-197
6. R.M. Ransohoff et al. Three or more routes for leukocyte migration into the central nervous system Nat. Rev. Immunol. 3 2003 569-581
7. M.L. Cuzner G. Opdenakker Plasminogen activators and matrix metalloproteinases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system J. Neuroimmunol. 94 1999 1-14
8. C. Lucchinetti et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann. Neurol. 47 2000 707-717
9. H. Neumann et al. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases Trends Neurosci. 25 2002 313-319
10. K.J. Smith H. Lassmann The role of nitric oxide in multiple sclerosis Lancet Neurol. 1 2002 232-241
11. F. Aboul-Enein H. Lassmann Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? Acta Neuropathol. (Berl.) 109 2004 49-55
12. A. Compston Genetic susceptibility and epidemiology R.A. Lazzarini Myelin Biology and Disorders Vol. 2 2004 Elsevier 701-734
13. D.S. Goodin et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines Neurology 58 2002 169-178
14. C. Confavreux et al. Relapses and progression of disability in multiple sclerosis N. Engl. J. Med. 343 2000 1430-1438
15. A. Kutzelnigg et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis Brain 128 2005 2705-2712
16. B. Serafini et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis Brain Pathol. 14 2004 164-174
17. M. Krumbholz et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma J. Exp. Med. 201 2005 195-200
18. Noseworthy, J. et al. (2006) Disease modifying treatments in multiple sclerosis. In Mc Alpine's Multiple Sclerosis (4th edn) (Compston, A., ed.), pp. 729-802, Churchill Livingstone Elsevier
19. T. Berger et al. Experimental autoimmune encephalomyelitis: The antigen specificity of T-lymphocytes determines the topography of lesions in the central and peripheral nervous system Lab. Invest. 76 1997 355-364
20. M.C. Zhong et al. Multiantigen/multiepitope-directed immune suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene J. Clin. Invest. 110 2002 81-90
21. O. Neuhaus et al. Mechanisms of action of glatiramer acetate in multiple sclerosis Neurology 56 2001 702-708
22. G. Moalem et al. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy Nat. Med. 5 1999 49-55
23. H. Wiendl R. Hohlfeld Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials BioDrugs 16 2002 183-200
24. H. Lassmann R.M. Ransohoff The CD4-Th1 model for multiple sclerosis: A critical [correction of crucial] re-appraisal Trends Immunol. 25 2004 132-137
25. M. Keegan et al. Humoral multiple sclerosis pathology correlates with response to therapeutic plasms exchange Lancet 366 2005 579-582
26. D.O. Willenborg et al. Our shifting understanding of the role of nitric oxide in autoimmune encephalomyelitis: A review J. Neuroimmunol. 100 1999 21-35
27. L. Probert et al. TNFR1 signalling is critical for the development of demyelination and the limitation of T-cell responses during immune-mediated CNS disease Brain 123 2000 2005-2019
28. C. Bjartmar B.D. Trapp Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences Curr. Opin. Neurol. 14 2001 271-278
29. T. Smith et al. Autoimmune encephalomyelitis ameliorated by AMPA antagonists Nat. Med. 6 2000 62-66
30. D.A. Bechtold et al. Axonal protection using flecainide in experimental autoimmune encephalomyelitis Ann. Neurol. 55 2004 607-616
31. B. Kornek et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions Am. J. Pathol. 157 2000 267-276
32. R.J. Franklin Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 3 2002 705-714
33. B. Bielekova et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand Nat. Med. 6 2000 1167-1175
34. L. Kappos et al. Induction of a non-encephalitogenic type 3 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial Nat. Med. 6 2000 1176-1182
35. M. Liang et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1 J. Biol. Chem. 275 2000 19000-19008
36. A. Coles et al. Campath-1H treatment of multiple sclerosis: Lessons from the bedside for the bench Clin. Neurol. Neurosurg. 106 2004 270-274
37. E. Beutler J.A. Koziol The cladribine trial in secondary progressive multiple sclerosis: A reanalysis Neuroepidemiology 19 2000 109-112
38. T. Chitnis S.J. Khoury Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis J. Allergy Clin. Immunol. 112 2003 837-849
39. J.W. Rose et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody Ann. Neurol. 56 2004 864-867
40. V. Brinkmann et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors J. Biol. Chem. 277 2002 21453-21457
41. Anonymous (2005) BG 12: BG 00012/Oral Fumarate, FAG.201, second-generation fumarate derivative - Fumapharm/Biogen Idec. Drugs RD 6, 229-230
42. D.A. Bechtold K.J. Smith Sodium-mediated axonal degeneration in inflammatory demyelinating diseases J. Neurol. Sci. 233 2005 27-35
43. C. Polman et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS Neurology 64 2005 987-991
44. V.W. Yong et al. The promise of minocycline in neurology Lancet Neurol. 3 2004 744-751
45. H.P. Hartung et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomized, multicentre trial Lancet 360 2002 2018-2025
46. D.S. Goodin et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology 61 2003 1332-1338
47. C.M. Dalton et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis J. Neurol. 251 2004 407-413
48. D.H. Miller et al. A controlled trial of natalizumab for relapsing multiple sclerosis N. Engl. J. Med. 348 2003 15-23
49. L. Steinman Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab Nat. Rev. Drug Discov. 4 2005 510-518
50. N.L. Sicotte et al. Treatment of multiple sclerosis with the pregnancy hormone estriol Ann. Neurol. 52 2002 421-428
51. R.E. Gonsette A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis Expert Opin. Pharmacother. 5 2004 747-765
52. J. Killestein et al. Glutamate inhibition in MS: The neuroprotective properties of riluzole J. Neurol. Sci. 233 2005 113-115
53. B.A. Cree et al. An open label study of the effects of rituximab in neuromyelitis optica Neurology 64 2005 1270-1272
54. J.M. Kovarik P. Burton Immunosuppressants in advanced clinical development for organ transplantation and selected autoimmune diseases Expert Opin. Emerg. Drugs 8 2003 47-62
55. C.L. Darlington The potential of statins in the treatment of multiple sclerosis Curr. Opin. Investig. Drugs 6 2005 667-671
56. A.A. Vandenbark TCR peptide vaccination in multiple sclerosis: Boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells Curr. Drug Targets Inflamm. Allergy 4 2005 217-229
57. L. Kappos et al. Alternatives to current disease-modifying treatments in MS: What do we need and what can we expect in the future J. Neurol. 251 Suppl. 5 2004 v57-v64
58. Multiple Sclerosis Therapy Consensus Group Escalating immunotherapy of multiple sclerosis: New aspects and practical implications J. Neurol. 251 2004 1329-1339